Kessler Exits Perrigo With Doors Open On Turnaround, Closed On Ireland, US Tax Disputes

At helm nearly five years with Perrigo continuing to navigate comprehensive turnaround with a target of returning to its historical profile of driving volume sales while keeping costs lower than is brand-name OTC drug competitors, he’s leaving at end of July.